{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:25:45Z","timestamp":1789863945288,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BC Ministry of Health, Community Crisis Innovation Fund"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["170288"],"award-info":[{"award-number":["170288"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["170288"],"award-info":[{"award-number":["170288"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["170288"],"award-info":[{"award-number":["170288"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite the implementation and expansion of public health and harm reduction strategies aimed at preventing and reversing overdoses, rates of overdose-related events and fatalities continue to rise in British Columbia. The COVID-19 pandemic created a second, concurrent public health emergency that further exacerbated the illicit drug toxicity crisis, reinforced existing social inequities and vulnerabilities, and highlighted the precariousness of systems in place that are meant to protect the health of communities. By exploring the perspectives of people with recent experience of illicit substance use, this study sought to characterize how the COVID-19 pandemic and associated public health measures influenced risk and protective factors related to unintentional overdose by altering the environment in which people live and use substances, influencing the ability of people who use substances to be safe and well.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One-on-one semi-structured interviews were conducted by phone or in-person with people who use illicit substances (n\u2009=\u200962) across the province. Thematic analysis was performed to identify factors shaping the overdose risk environment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Participants pointed to factors that increased risk of overdose, including: [1] physical distancing measures that created social and physical isolation and led to more substance use alone without bystanders nearby able to respond in the event of an emergency; [2] early drug price spikes and supply chain issues that created inconsistencies in drug availability; [3] increasing toxicity and impurities in unregulated substances; [4] restriction of harm reduction services and supply distribution sites; and [5] additional burden placed on peer workers on the frontlines of the illicit drug toxicity crisis. Despite these challenges, participants highlighted factors that protected against overdose and substance-related harm, including the emergence of new programs, the resiliency of communities of people who use substances who expanded their outreach efforts, the existence of established social relationships, and the ways that individuals consistently prioritized overdose response over concerns about COVID-19 transmission to care for one another.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The findings from this study illustrate the complex contextual factors that shape overdose risk and highlight the importance of ensuring that the needs of people who use substances are addressed in future public health emergency responses.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-023-15474-5","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T18:03:19Z","timestamp":1680544999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["\u201cIt\u2019s just a perfect storm\u201d: Exploring the consequences of the COVID-19 pandemic on overdose risk in British Columbia from the perspectives of people who use substances"],"prefix":"10.1186","volume":"23","author":[{"given":"Annie","family":"Foreman-Mackey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Corser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amiti","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"McDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheri","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"Buxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"15474_CR1","unstructured":"BC Ministry of Health. Provincial health officer declares public health emergency. BC Gov News [Internet]. 2016 Apr 14 [cited 2021 Jul 16]; Available from: https:\/\/news.gov.bc.ca\/releases\/2016HLTH0026-000568"},{"key":"#cr-split#-15474_CR2.1","unstructured":"BC Coroners Service. Illicit Drug Toxicity Deaths in BC: January 1, 2012 - February 28, 2022 [Internet]. Ministry of Public Safety & Solicitor General"},{"key":"#cr-split#-15474_CR2.2","unstructured":"2022 [cited 2022 Apr 24]. Available from: https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/illicit-drug.pdf"},{"key":"#cr-split#-15474_CR3.1","unstructured":"BC Coroners Service. Illicit Drug Toxicity: Type of Drug Data (Data to August 31, 2022) [Internet]. Ministry of Public Safety & Solicitor General"},{"key":"#cr-split#-15474_CR3.2","unstructured":"2022 [cited 2022 Dec 27]. Available from: https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/illicit-drug-type.pdf"},{"key":"15474_CR4","doi-asserted-by":"crossref","unstructured":"Enns A, Pinto A, Venugopal J, Grywacheski V, Gheorghe M, Kakkar T, et al. Substance use and related harms in the context of COVID-19: a conceptual model. Health Promot Chronic Dis Prev Can. 2020 Sep;40(11\/12):342\u20139.","DOI":"10.24095\/hpcdp.40.11\/12.03"},{"key":"15474_CR5","doi-asserted-by":"crossref","unstructured":"Nguyen T, Buxton JA. Pathways between COVID-19 public health responses and increasing overdose risks: a rapid review and conceptual framework. Int J Drug Policy. 2021 Jul;93:103236.","DOI":"10.1016\/j.drugpo.2021.103236"},{"key":"15474_CR6","doi-asserted-by":"crossref","unstructured":"Chang J, Agliata J, Guarinieri M. COVID-19 - enacting a \u2018new normal\u2019 for people who use drugs. Int J Drug Policy. 2020 Sep;83:102832.","DOI":"10.1016\/j.drugpo.2020.102832"},{"key":"15474_CR7","doi-asserted-by":"crossref","unstructured":"Norton A, Kerr T. Applying the lessons of COVID-19 response to Canada\u2019s worsening opioid epidemic. EClinicalMedicine. 2020 Dec;29\u201330:100633.","DOI":"10.1016\/j.eclinm.2020.100633"},{"key":"15474_CR8","doi-asserted-by":"crossref","unstructured":"MacKinnon L, Soc\u00edas ME, Bardwell G. COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings. J Subst Abuse Treat. 2020 Dec;119:108153.","DOI":"10.1016\/j.jsat.2020.108153"},{"key":"15474_CR9","doi-asserted-by":"crossref","unstructured":"Melamed OC, Hauck TS, Buckley L, Selby P, Mulsant BH. COVID-19 and persons with substance use disorders: Inequities and mitigation strategies.Subst Abuse. 2020 Jul2;41(3):286\u201391.","DOI":"10.1080\/08897077.2020.1784363"},{"key":"15474_CR10","doi-asserted-by":"crossref","unstructured":"Slaunwhite AK, Gan WQ, Xavier C, Zhao B, Buxton JA, Desai R. Overdose and risk factors for coronavirus disease 2019. Drug Alcohol Depend. 2020 Jul;212:108047.","DOI":"10.1016\/j.drugalcdep.2020.108047"},{"key":"15474_CR11","unstructured":"United Nationals Office of the High Commissioner for Human Rights. Statement by the UN expert on the right to health on the protection of people who use drugs during the COVID-19 pandemic [Internet]. Officer of the High Commissioner for Human Rights; 2020 [cited 2021 Jul 15]. Available from: https:\/\/www.ohchr.org\/EN\/NewsEvents\/Pages\/DisplayNews.aspx?NewsID=25797&LangID=E"},{"key":"15474_CR12","doi-asserted-by":"crossref","unstructured":"Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020 Jul;7(1):61\u20132.","DOI":"10.7326\/M20-1212"},{"key":"15474_CR13","doi-asserted-by":"crossref","unstructured":"Tyndall M. Safer opioid distribution in response to the COVID-19 pandemic. Int J Drug Policy. 2020 Sep;83:102880.","DOI":"10.1016\/j.drugpo.2020.102880"},{"key":"15474_CR14","doi-asserted-by":"crossref","unstructured":"Bonn M, Palayew A, Touesnard N, Tyndall M. Addressing the Syndemic of HIV, Hepatitis C. Overdose, and COVID-19 Among People Who Use Drugs: The Potential Roles for Decriminalization and Safe Supply. J Stud ALCOHOL DRUGS. 2020;5.","DOI":"10.15288\/jsad.2020.81.556"},{"key":"15474_CR15","doi-asserted-by":"crossref","unstructured":"Wakeman SE, Green TC, Rich J. An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. Nat Med. 2020 Jun;26(6):819\u201320.","DOI":"10.1038\/s41591-020-0898-0"},{"key":"15474_CR16","unstructured":"BC Centre for Disease Control. Dual public health emergencies: Overdose in BC during COVID-19 [Internet]. BC Centre for Disease Control; 2021 [cited 2021 Jul 15]. Available from: http:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Statistics%20and%20Research\/Statistics%20and%20Reports\/Overdose\/2021.04.16_Infographic_OD%20Dashboard.pdf"},{"key":"15474_CR17","unstructured":"Canadian Centre on Substance Use and Addiction. Impacts of the COVID-19 pandemic on people who use substances: What we heard. Can Cent Subst Use Addict [Internet]. 2020 [cited 2021 Jul 15]; Available from: https:\/\/www.ccsa.ca\/sites\/default\/files\/2020-07\/CCSA-COVID-19-Impacts-on-People-Who-Use-Substances-Report-2020-en.pdf"},{"key":"15474_CR18","doi-asserted-by":"crossref","unstructured":"Genberg BL, Astemborski J, Piggott DA, Woodson-Adu T, Kirk GD, Mehta SH. The health and social consequences during the initial period of the COVID-19 pandemic among current and former people who inject drugs: a rapid phone survey in Baltimore, Maryland. Drug Alcohol Depend. 2021 Apr;221:108584.","DOI":"10.1016\/j.drugalcdep.2021.108584"},{"key":"15474_CR19","doi-asserted-by":"crossref","unstructured":"Grebely J. COVID-19 and the health of people who use drugs_ What is and what could be?Int J Drug Policy. 2020;10.","DOI":"10.1016\/j.drugpo.2020.102958"},{"key":"15474_CR20","doi-asserted-by":"crossref","unstructured":"Rhodes T. The \u2018risk environment\u2019: a framework for understanding and reducing drug-related harm. Int J Drug Policy. 2002 Jun;13(2):85\u201394.","DOI":"10.1016\/S0955-3959(02)00007-5"},{"issue":"3","key":"15474_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.drugpo.2008.10.003","volume":"20","author":"T Rhodes","year":"2009","unstructured":"Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20(3):193\u2013201.","journal-title":"Int J Drug Policy"},{"key":"15474_CR22","doi-asserted-by":"crossref","unstructured":"Collins AB. The intersectional risk environment of people who use drugs.Soc Sci. 2019;10.","DOI":"10.1016\/j.socscimed.2019.112384"},{"issue":"6","key":"15474_CR23","first-page":"207","volume":"62","author":"J Buxton","year":"2020","unstructured":"Buxton J, Moe J, Papamihali K, Kuo M. The physicians role in supporting people who use substances in a dual public health emergency. BC Med J. 2020;62(6):207\u20138.","journal-title":"BC Med J"},{"key":"15474_CR24","doi-asserted-by":"crossref","unstructured":"Ali F, Russell C, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada. Int J Drug Policy. 2021 Jul;93:103237.","DOI":"10.1016\/j.drugpo.2021.103237"},{"key":"15474_CR25","doi-asserted-by":"crossref","unstructured":"Galarneau LR, Hilburt J, O\u2019Neill ZR, Buxton JA, Scheuermeyer FX, Dong K et al. Experiences of people with opioid use disorder during the COVID-19 pandemic: A qualitative study. Leong C, editor. PLOS ONE. 2021 Jul 29;16(7):e0255396.","DOI":"10.1371\/journal.pone.0255396"},{"key":"15474_CR26","doi-asserted-by":"crossref","unstructured":"Kesten JM, Holland A, Linton MJ, Family H, Scott J, Horwood J, et al. Living under coronavirus and injecting drugs in Bristol (LUCID-B): a qualitative study of experiences of COVID-19 among people who inject drugs. Int J Drug Policy. 2021 Dec;98:103391.","DOI":"10.1016\/j.drugpo.2021.103391"},{"key":"15474_CR27","doi-asserted-by":"crossref","unstructured":"Russell C, Ali F, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): a national qualitative study. J Subst Abuse Treat. 2021 Oct;129:108374.","DOI":"10.1016\/j.jsat.2021.108374"},{"key":"15474_CR28","doi-asserted-by":"crossref","unstructured":"Corser J, Palis H, Fleury M, Lamb J, Lock K, McDougall J, et al. Identifying behaviours for survival and wellness among people who use methamphetamine with opioids in British Columbia: a qualitative study. Harm Reduct J. 2022 Dec;19(1):46.","DOI":"10.1186\/s12954-022-00630-8"},{"key":"15474_CR29","doi-asserted-by":"crossref","unstructured":"Ackermann E, Kievit B, Xavier J, Barbic S, Ferguson M, Greer A, et al. Awareness and knowledge of the good Samaritan Drug Overdose Act among people at risk of witnessing an overdose in British Columbia, Canada: a multi-methods cross sectional study. Subst Abuse Treat Prev Policy. 2022 Dec;17(1):42.","DOI":"10.1186\/s13011-022-00472-4"},{"key":"15474_CR30","doi-asserted-by":"crossref","unstructured":"Guest G, MacQueen KM, Namey EE. Applied Thematic Analysis [Internet]. SAGE Publications Inc.; 2012. Available from: https:\/\/methods.sagepub.com\/book\/applied-thematic-analysis","DOI":"10.4135\/9781483384436"},{"key":"15474_CR31","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006 Jan;3(2):77\u2013101.","DOI":"10.1191\/1478088706qp063oa"},{"key":"15474_CR32","unstructured":"Statistics Canada. Population Centre and Rural Area Classification, [Internet]. 2016 [cited 2022 Apr 25]. Available from: https:\/\/www.statcan.gc.ca\/en\/subjects\/standard\/pcrac\/2016\/introduction#s3"},{"key":"15474_CR33","unstructured":"BC Ministry of Health. BC Ministry of Health Geographies: BC Health Information Map [Internet]. 2021 [cited 2022 Apr 25]. Available from: https:\/\/www.arcgis.com\/apps\/MapSeries\/index.html?appid=9b626376507e4e84baeaac94ba614b4b"},{"key":"15474_CR34","doi-asserted-by":"crossref","unstructured":"Ferguson M, Parmar A, Papamihali K, Weng A, Lock K, Buxton JA. Investigating opioid preference to inform safe supply services: a cross sectional study. Int J Drug Policy. 2022 Mar;101:103574.","DOI":"10.1016\/j.drugpo.2021.103574"},{"key":"15474_CR35","unstructured":"BC Centre on Substance Use. Risk Mitigation in the Context of Dual Public Health Emergencies: Interim Clinical Guidance: Version 1.5. BC Cent Subst Use. 2020 Mar"},{"key":"15474_CR36","doi-asserted-by":"crossref","unstructured":"Logie CH, Turan JM. How do we Balance tensions between COVID-19 public health responses and Stigma Mitigation? Learning from HIV Research. AIDS Behav. 2020 Jul;24(7):2003\u20136.","DOI":"10.1007\/s10461-020-02856-8"},{"key":"15474_CR37","doi-asserted-by":"crossref","unstructured":"Moe J, Buxton J. Don\u2019t forget our dual public health crises.Can J Emerg Med. 2020;22(4).","DOI":"10.1017\/cem.2020.369"},{"key":"15474_CR38","doi-asserted-by":"crossref","unstructured":"Mykhalovskiy E, Kazatchkine C, Foreman-Mackey A, McClelland A, Peck R, Hastings C, et al. Human rights, public health and COVID-19 in Canada. Can J Public Health. 2020 Dec;111(6):975\u20139.","DOI":"10.17269\/s41997-020-00408-0"},{"key":"15474_CR39","doi-asserted-by":"crossref","unstructured":"Papamihali K, Yoon M, Graham B, Karamouzian M, Slaunwhite AK, Tsang V, et al. Convenience and comfort: reasons reported for using drugs alone among clients of harm reduction sites in British Columbia, Canada. Harm Reduct J. 2020 Dec;17(1):90.","DOI":"10.1186\/s12954-020-00436-6"},{"key":"#cr-split#-15474_CR40.1","unstructured":"BC Coroners Service. Illicit drug toxicity type of drug data: data to Feb 28, 2022 [Internet]. Ministry of Public Safety & Solicitor General"},{"key":"#cr-split#-15474_CR40.2","unstructured":"2022 [cited 2022 Apr 25]. Available from: https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/illicit-drug-type.pdf"},{"issue":"4","key":"15474_CR41","first-page":"177","volume":"63","author":"R Purssell","year":"2021","unstructured":"Purssell R, Buxton J, Godwin J, Moe J. Potent sedatives in opioids in BC: implications for resuscitation, and benzodiazepine and etizolam withdrawal. BC Med J. 2021;63(4):177\u20138.","journal-title":"BC Med J"},{"key":"15474_CR42","doi-asserted-by":"crossref","unstructured":"Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020 Dec;17(1):26.","DOI":"10.1186\/s12954-020-00370-7"},{"key":"15474_CR43","doi-asserted-by":"crossref","unstructured":"Whitfield M. The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England.Int J Drug Policy. 2020;4.","DOI":"10.1016\/j.drugpo.2020.102851"},{"key":"15474_CR44","unstructured":"Office of the Provincial Health Officer and BC Centre for Disease Control. Examining the Societal Consequences of the COVID-19 Pandemic: Increased Overdose Harms and Death, July 2021 [Internet]. 2021 [cited 2022 Apr 25]. Available from: http:\/\/www.bccdc.ca\/Health-Professionals-Site\/Documents\/societal_consequences\/Increased-Overdoses.pdf"},{"key":"15474_CR45","doi-asserted-by":"crossref","unstructured":"Chan Carusone S, Guta A, Robinson S, Tan DH, Cooper C, O\u2019Leary B, et al. Maybe if I stop the drugs, then maybe they\u2019d care?\u201d\u2014hospital care experiences of people who use drugs. Harm Reduct J. 2019 Dec;16(1):16.","DOI":"10.1186\/s12954-019-0285-7"},{"key":"15474_CR46","doi-asserted-by":"crossref","unstructured":"Dannatt L, Ransing R, Calvey T, Scheibein F, Saad NA, Shirasaka T, et al. The impact of Stigma on Treatment Services for People with Substance Use Disorders during the COVID-19 pandemic\u2014perspectives of NECPAM Members. Front Psychiatry. 2021 Mar;2:12:634515.","DOI":"10.3389\/fpsyt.2021.634515"},{"key":"15474_CR47","doi-asserted-by":"crossref","unstructured":"Perri M, Kaminski N, Bonn M, Kolla G, Guta A, Bayoumi AM, et al. A qualitative study on overdose response in the era of COVID-19 and beyond: how to spot someone so they never have to use alone. Harm Reduct J. 2021 Dec;18(1):85.","DOI":"10.1186\/s12954-021-00530-3"},{"key":"15474_CR48","doi-asserted-by":"crossref","unstructured":"Kerr T, Mitra S, Kennedy MC, McNeil R. Supervised injection facilities in Canada: past, present, and future. Harm Reduct J. 2017 Dec;14(1):28.","DOI":"10.1186\/s12954-017-0154-1"},{"key":"15474_CR49","doi-asserted-by":"crossref","unstructured":"Kerr T, Small W, Peeace W, Douglas D, Pierre A, Wood E. Harm reduction by a \u201cuser-run\u201d organization: a case study of the Vancouver Area Network of Drug users (VANDU). Int J Drug Policy. 2006 Mar;17(2):61\u20139.","DOI":"10.1016\/j.drugpo.2006.01.003"},{"key":"15474_CR50","doi-asserted-by":"crossref","unstructured":"Kennedy MC, Boyd J, Mayer S, Collins A, Kerr T, McNeil R. Peer worker involvement in low-threshold supervised consumption facilities in the context of an overdose epidemic in Vancouver, Canada. Soc Sci Med. 2019 Mar;225:60\u20138.","DOI":"10.1016\/j.socscimed.2019.02.014"},{"key":"15474_CR51","doi-asserted-by":"crossref","unstructured":"Kolla G, Strike C. It\u2019s too much, I\u2019m getting really tired of it\u2019: overdose response and structural vulnerabilities among harm reduction workers in community settings. Int J Drug Policy. 2019 Dec;74:127\u201335.","DOI":"10.1016\/j.drugpo.2019.09.012"},{"key":"15474_CR52","doi-asserted-by":"crossref","unstructured":"Mamdani Z, McKenzie S, Pauly B, Cameron F, Conway-Brown J, Edwards D, et al. Running myself ragged\u201d: stressors faced by peer workers in overdose response settings. Harm Reduct J. 2021 Dec;18(1):18.","DOI":"10.1186\/s12954-020-00449-1"},{"key":"15474_CR53","doi-asserted-by":"publisher","unstructured":"Kelly PJA, Pilla J, Otor A, Hoadley A, Bauerle Bass S. \u201cWe figured it out as we went along\u201d: Staff perspectives of COVID-19 response efforts at a large North American syringe services programme. Health Soc Care Community [Internet]. 2022 Nov [cited 2023 Mar 10];30(6). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/hsc.13864","DOI":"10.1111\/hsc.13864"},{"key":"15474_CR54","doi-asserted-by":"crossref","unstructured":"Greer A, Bungay V, Pauly B, Buxton J. Peer\u2019 work as precarious: a qualitative study of work conditions and experiences of people who use drugs engaged in harm reduction work. Int J Drug Policy. 2020 Nov;85:102922.","DOI":"10.1016\/j.drugpo.2020.102922"},{"key":"15474_CR55","doi-asserted-by":"crossref","unstructured":"Greer AM, Luchenski SA, Amlani AA, Lacroix K, Burmeister C, Buxton JA. Peer engagement in harm reduction strategies and services: a critical case study and evaluation framework from British Columbia, Canada. BMC Public Health. 2016 Dec;16(1):452.","DOI":"10.1186\/s12889-016-3136-4"},{"key":"15474_CR56","doi-asserted-by":"crossref","unstructured":"Bardwell G. Women\u2019s multiple uses of an overdose prevention technology to mitigate risks and harms within a supportive housing environment: a qualitative study. 2021;9.","DOI":"10.1186\/s12905-021-01196-6"},{"issue":"5","key":"15474_CR57","doi-asserted-by":"publisher","first-page":"e20183","DOI":"10.2196\/20183","volume":"10","author":"S Bristowe","year":"2021","unstructured":"Bristowe S, Ghosh S, Trew M, Rittenbach K. Virtual overdose response for people who use opioids alone: protocol for a feasibility and clinical Trial Study. JMIR Res Protoc. 2021;10(5):e20183.","journal-title":"JMIR Res Protoc"},{"key":"15474_CR58","doi-asserted-by":"crossref","unstructured":"Schwartz DG, Ataiants J, Roth A, Marcu G, Yahav I, Cocchiaro B, et al. Layperson reversal of opioid overdose supported by smartphone alert: a prospective observational cohort study. EClinicalMedicine. 2020 Aug;25:100474.","DOI":"10.1016\/j.eclinm.2020.100474"},{"key":"15474_CR59","doi-asserted-by":"crossref","unstructured":"Gillett NP, Cannon AJ, Malinina E, Schnorbus M, Anslow F, Sun Q, et al. Human influence on the 2021 British Columbia floods. Weather Clim Extrem. 2022 Jun;36:100441.","DOI":"10.1016\/j.wace.2022.100441"},{"key":"15474_CR60","doi-asserted-by":"crossref","unstructured":"McNeil R, Fleming T, Mayer S, Barker A, Mansoor M, Betsos A, et al. Implementation of Safe Supply Alternatives during intersecting COVID-19 and Overdose Health Emergencies in British Columbia, Canada, 2021. Am J Public Health. 2022 Apr;112(S2):151\u20138.","DOI":"10.2105\/AJPH.2021.306692"},{"key":"15474_CR61","unstructured":"Health Canada. B.C. receives exemption to decriminalize possession of some illegal drugs for personal use. Government of Canada [Internet]. 2022 Jun 1 [cited 2022 Sep 25]; Available from: https:\/\/www.canada.ca\/en\/health-canada\/news\/2022\/05\/bc-receives-exemption-to-decriminalize-possession-of-some-illegal-drugs-for-personal-use.html"},{"key":"15474_CR62","unstructured":"Pivot L, Society HIVL, Network. Canadian Drug Policy Coalition. Drug Decriminalization: A Necessary Response to COVID-19 [Internet]. 2020 [cited 2022 Apr 25]. Available from: https:\/\/www.pivotlegal.org\/drug_decriminalization_response_covid-19"},{"key":"15474_CR63","doi-asserted-by":"crossref","unstructured":"Parkin S, Kimerg\u00e5rd A. A critical analysis of respondent quotes used as titles of qualitative research papers that are published in peer-reviewed journals. Account Res. 2022 Feb 17;29(2):109\u201332.","DOI":"10.1080\/08989621.2021.1901224"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-15474-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-023-15474-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-15474-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T18:04:49Z","timestamp":1680545089000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-023-15474-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["15474"],"URL":"https:\/\/doi.org\/10.1186\/s12889-023-15474-5","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"18 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols and procedures were approved by the University of British Columbia\u2019s research ethics board (CUT Meth OD \u2013 H20-01475 and GSDOA \u2013 H19-01842) and all methods were carried out in accordance with relevant guidelines, including COVID-19 protocols. Informed consent was obtained from all subjects before proceeding with qualitative interviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"640"}}